PDCD1 and hepatocellular carcinoma: This suggests that targeting of PD-1 or its ligand in HCC can occasionally be successful, and resistance to anti-PD-1/PD-1 ligand monotherapy in HCC may be overcome by combination of agents directed simultaneously against these co-inhibitory and co-stimulatory checkpoint signals.